Haldol

Haldol is the commercial name for the antipsychotic medication haloperidol, supplied in an intramuscular formulation for use in the European Union. It is presented as a sterile solution intended for injection by a healthcare professional. The product contains haloperidol as the sole active ingredient and is typically used when rapid drug delivery is required. Haldol is classified as a typical antipsychotic in clinical practice settings.

Haldol intramuscular injection is employed in several psychiatric and neurologic situations where a rapid onset of action is desired.

- Management of acute agitation associated with schizophrenia or other psychotic disorders. - Control of severe manic episodes in bipolar disorder when oral therapy is insufficient. - Treatment of acute psychosis in patients unable to take oral medication. - Adjunctive therapy for severe behavioral disturbances in dementia or delirium. - Short‑term use for pre‑operative sedation in selected cases.

Side effects of haloperidol administered intramuscularly vary in frequency and severity, ranging from mild, transient reactions to rare but serious events.

Common: - Drowsiness or sedation, often occurring shortly after injection. - Restlessness or akathisia, presenting as an inner sense of unease. - Dry mouth and reduced salivation. - Blurred vision or mild visual disturbances. - Constipation or gastrointestinal slowdown.

Serious: - Extrapyramidal symptoms such as acute dystonia, rigidity, or parkinsonism. - Neuroleptic malignant syndrome, characterized by fever, muscle rigidity, and autonomic instability. - Cardiac arrhythmias, including QT interval prolongation and potential torsades de pointes. - Severe hypotension or orthostatic dizziness.

When using intramuscular haloperidol, clinicians should evaluate patient history and monitor for specific safety concerns to minimize risk.

- Assess for a history of cardiovascular disease, especially arrhythmias. - Evaluate for prior extrapyramidal reactions or movement disorders. - Use caution in patients with hepatic or renal impairment. - Monitor elderly patients closely due to increased sensitivity and risk of delirium. - Avoid use in individuals with known hypersensitivity to haloperidol or its excipients. - Consider pregnancy and lactation status, as safety data are limited. - Ensure appropriate dosing intervals to reduce accumulation.

Haloperidol can interact with several medications, affecting its efficacy or increasing the likelihood of adverse effects.

Avoid: - Concurrent use with other potent dopamine antagonists, which may amplify extrapyramidal side effects. - Co‑administration with drugs that significantly prolong the QT interval, such as certain antiarrhythmics or macrolide antibiotics. - Combining with strong CYP3A4 inhibitors that raise haloperidol plasma levels.

Use with caution: - Use with CYP3A4 inducers (e.g., carbamazepine, phenytoin) as they may reduce therapeutic effect. - Concomitant use of central nervous system depressants, including benzodiazepines or opioids, may enhance sedation. - Interaction with anticholinergic agents may mask early signs of extrapyramidal symptoms.